Theralase® Releases FY2022 Audited Financial Statements
April 26, 2023 18:01 ET
|
Theralase Technologies Inc.
TORONTO, April 26, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase® Awarded TSX Venture 50™ Recognition as a Top Performing Company
February 21, 2023 07:35 ET
|
Theralase Technologies Inc.
TORONTO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the ASCO GU Cancer Symposium
January 25, 2023 07:00 ET
|
Theralase Technologies Inc.
TORONTO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Theralase Releases Q222 Interim Financial Statements
August 29, 2022 19:45 ET
|
Theralase Technologies Inc.
TORONTO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase Expands Intellectual Property Portfolio
June 28, 2022 07:00 ET
|
Theralase Technologies Inc.
TORONTO, June 28, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Theralase® Research - One of the Top 10 Most Downloaded Papers
June 24, 2022 07:00 ET
|
Theralase Technologies Inc.
TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase® Phase Ib NMIBC Clinical Study Published
June 21, 2022 07:00 ET
|
Theralase Technologies Inc.
TORONTO, June 21, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase Releases Q122 Interim Financial Statements
May 30, 2022 17:53 ET
|
Theralase Technologies Inc.
TORONTO, May 30, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase Release FY2021 Audited Financial Statements
April 29, 2022 21:11 ET
|
Theralase Technologies Inc.
TORONTO, April 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase® Provides Update on Phase II Bladder Cancer Clinical Study
April 05, 2022 07:00 ET
|
Theralase Technologies Inc.
TORONTO, April 05, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...